For the half-year to 31 December 2014, the IPKat's regular team is supplemented by contributions from guest bloggers Rebecca Gulbul, Lucas Michels and Marie-Andrée Weiss.

Regular round-ups of the previous week's blogposts are kindly compiled by Alberto Bellan.

Monday, 29 November 2004

ISRAEL IN IP DISPUTE

The Jerusalem Post reports that Israeli Industry, Trade and Labor Minister Ehud Olmert will be meeting US trade representative Robert Zoellick today. At the same time, Ministry officials will be meeting with EU representatives. The subject of discussion is Israel’s upcoming new intellectual property legislation. The US and EU are calling for Israel to introduce data exclusivity, which protects the confidentiality of proprietary tests and clinical trial data used by a pharmaceutical firm while registering a drug. This protection prevents generic drug companies from using this data to develop the same drug for a specified period. The US provides a 5 year protection period, while the EU grants 10 years. However, Israel is proposing to only grant market exclusivity, which protects pharmaceutical products but not data.

The IPKat notes that while TRIPS Art.39(3) requires Member States to protect data disclosed in clinical or other trials, it does not specify the term of protection that is necessary.

More on data exclusivity here
The IPKat reveals more clinical secrets here, here and here

3 comments:

Anonymous said...

Think that could give you some Search Engine popularity, and traffic???

Anonymous said...

Learn how to quickly create an RSS feeds with our RSS feeder, for high link popularity and ultimately better search engine rankings.

Anonymous said...

a lot of premium products and services being offered for free. What’s best is that there is a seemingly

Subscribe to the IPKat's posts by email here

Just pop your email address into the box and click 'Subscribe':